2025-04-10 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Analysis

This report analyzes Teva Pharmaceutical Industries Ltd ADR (TEVA), a generic and specialty pharmaceutical company.

**1) Performance Comparison & Alpha/Beta Analysis:**

TEVA's cumulative return is 36.39%, significantly underperforming the S&P 500 (VOO) with a cumulative return of 66.94%.  The difference is -30.6%, placing it at the 63.6th percentile of its historical range of underperformance relative to the S&P 500 (-122.3% to 21.9%).

The Alpha/Beta analysis reveals consistently negative alpha values across the observed periods, indicating underperformance relative to the market benchmark.  The beta values fluctuate, suggesting varying levels of market sensitivity. Notably, the high CAGR in 2022-2024 is offset by significant maximum drawdown (MDD) values in earlier periods, highlighting the risk associated with TEVA. The market capitalization (Cap) shows some volatility, reflecting the company's performance fluctuations.

| Year       | CAGR    | MDD     | Alpha | Beta | Cap(B) |
|------------|---------|---------|-------|-------|--------|
| 2015-2017  | -44.0%  | 58.4%   | -73.0% | -0.0  | 21.7   |
| 2016-2018  | -41.0%  | 70.4%   | -59.0% | -0.1  | 17.7   |
| 2017-2019  | -16.0%  | 70.4%   | -45.0% | -0.2  | 11.2   |
| 2018-2020  | 0.0%    | 70.4%   | -25.0% | -0.2  | 11.1   |
| 2019-2021  | -22.0%  | 58.3%   | -76.0% | -0.2  | 9.2    |
| 2020-2022  | 27.0%   | 74.8%   | 20.0%  | -0.2  | 10.4   |
| 2021-2023  | 38.0%   | 74.8%   | 21.0%  | -0.8  | 12.0   |
| 2022-2024  | 122.0%  | 74.8%   | 106.0% | -0.7  | 25.2   |
| 2023-2025  | 46.0%   | 76.0%   | 32.0%  | -0.0  | 16.2   |


**2) Recent Price Movement:**

* **Closing Price:** $14.16
* **5-Day Moving Average:** $14.07
* **20-Day Moving Average:** $15.45
* **60-Day Moving Average:** $17.08

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a downtrend. The recent price increase of 4.19% from the previous close might indicate a temporary bounce.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.5289 (High Risk)
* **RSI:** 25.47 (Oversold territory)
* **PPO:** -0.9551 (Bearish signal)
* **Relative Strength Change (20-day):** -2.5 (Short-term downtrend)
* **Expected Return (2+ years):** -40.9% relative to the S&P 500.  This suggests significant underperformance is expected even with a long-term investment horizon.  The recent price jump is not reflected in this long-term forecast.

The combination of overbought RSI, negative PPO, and high MRI suggests a bearish outlook in the short to medium term.  The large negative expected return needs to be taken seriously. The recent price jump of 4.19% suggests potential volatility and should be viewed with caution.


**4) Recent Earnings Analysis:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-11-06 | -$0.39   | $4.33 B     |
| 2024-07-31 | -$0.75   | $4.16 B     |
| 2024-05-08 | -$0.12   | $3.82 B     |
| 2023-11-09 | $0.07    | $3.85 B     |
| 2024-02-12 | $0.06    | $3.85 B     |

Recent earnings show significant volatility with both losses and small profits.  Revenue remains relatively stable, but profitability is a major concern.  The negative EPS in several quarters warrants further investigation into the underlying causes.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2024-12-31  | $4.23B    | 50.15%        |
| 2024-09-30  | $4.33B    | 49.60%        |
| 2024-06-30  | $4.16B    | 48.61%        |
| 2024-03-31  | $3.82B    | 46.37%        |
| 2023-12-31  | $4.46B    | 54.18%        |

Revenue shows some fluctuation but generally remains consistent. Profit margins have declined in the past year.


**Capital and Profitability:**

| Quarter     | Equity    | ROE          |
|-------------|-----------|---------------|
| 2024-12-31  | $5.37B    | -4.04%        |
| 2024-09-30  | $6.07B    | -7.21%        |
| 2024-06-30  | $6.36B    | -13.30%       |
| 2024-03-31  | $7.28B    | -1.91%        |
| 2023-12-31  | $7.51B    | 5.72%         |

Negative ROE in recent quarters is a significant warning sign, indicating the company is not generating sufficient returns on its equity.


**6) Overall Summary:**

TEVA shows substantial underperformance relative to the S&P 500, with negative alpha and volatile beta. Technical indicators point to a bearish short-term outlook, while the long-term forecast is even more negative.  Recent earnings reveal inconsistent profitability and declining ROE.  While revenue remains relatively stable, the company's negative EPS and declining profit margins represent substantial risks. The high market risk indicator further strengthens the bearish outlook.  Investors should proceed with extreme caution.  Further investigation into the causes of the negative EPS and ROE is strongly recommended before considering any investment.
